M42 will combine G42 Healthcare and Mubadala Health assets to create a tech-enabled, integrated healthcare company.
Abu Dhabi’s G42 and Mubadala Investment Company have partnered to create a tech-enabled integrated healthcare company, M42. The company combines G42 Healthcare’s medical and data-centric technologies with Mubadala Health’s patient services and advanced facilities. M42’s aim is to provide personalized, precise, and preventive care, revolutionizing the way medical care is delivered.
M42 combines healthcare assets for personalized, precise care
M42 will manage assets that include Amana Healthcare, Biogenix Labs, Danat Al Emarat, HealthPoint Hospital, the HealthPlus network of specialty centers, Moorfields Eye Hospital Abu Dhabi, Imperial College London Diabetes Centre, Insights Research Organisation & Solutions (IROS), Omics Centre of Excellence, and The National Reference Laboratory, among others.
The company will explore global expansion and collaborate with healthcare, pharmaceutical, and healthtech leaders to bring high-quality care to communities worldwide. It will be led by group CEO and managing director Hasan Jasem Al Nowais.
“Our vision is to transform lives through innovation by providing personalized, and precise patient care,” said Al Nowais. “We are confident that through our operating companies, M42 will create a future in which dedicated healthcare professionals are empowered by the latest technology to optimise patient outcomes.”
M42 aims to expand collaborate with healthcare leaders
M42 aims to enhance patient services across the continuum of care by utilizing the strength of the combined network of G42 and Mubadala, which currently serves hundreds of thousands of patients through their vast network of healthcare facilities and digital platforms. Additionally, M42 will partner with top researchers and pharmaceutical and healthtech ecosystems to provide world-class care to local communities.